Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
11 April 2025 | Story Onthatile Tikoe | Photo Onthatile Tikoe
Zane Dippenaar
Dr Zané Dippenaar (30) is the youngest PhD graduate in this year’s Business Management class from the University of the Free State.

Zané Dippenaar, a 30-year-old marketing and project manager at a Cape Town-based solar energy company, is the youngest person in this year’s graduating class to earn a Doctor of Philosophy (PhD) in Business Management degree from the University of the Free State this year.  

But despite this achievement, the newly minted Dr Dippenaar says she would not have predicted she would study her way to PhD level. 

“I wasn’t particularly academically driven before tertiary education, but I knew from early on that I wanted to either become a teacher or pursue something in the world of business,” she says. Her natural ability and her family’s encouragement led her to explore entrepreneurship and marketing, which she soon developed a passion for.

 

Overcoming challenges and finding support

Dr Dippenaar’s academic journey was marked by significant challenges, including balancing work and study commitments. However, she credits her supervisors and family for helping her stay motivated. 

Her dissertation, titled ‘Advertising and Brand Loyalty in the South African Solar Industry’, showcases her expertise in marketing and branding.

“There were moments filled with doubt, setbacks, and exhaustion, but I was fortunate to have a strong support system who continuously encouraged me and reminded me of what I was working towards,” she says.

 

Achieving a personal milestone

Dr Dippenaar’s PhD achievement is not only an academic milestone but also a personal triumph. She had set a goal of completing her PhD before turning 30 and achieved it just weeks before her birthday. “That was a personal milestone I had set for myself, and achieving it was incredibly fulfilling,” she says. 

She plans to apply the knowledge she gained in the industry and potentially return to academia. She advises younger students to trust their instincts and start their academic journey without waiting for perfection.

“Don’t wait until you’re ‘ready’ – you never will be. Just start. Surround yourself with people who believe in you, ask for help when you need it, and take it one chapter at a time,” she advises.

 

A role model for others

Dr Dippenaar hopes to inspire others, particularly young women, by showing that success in academia doesn’t follow a one-size-fits-all formula. “I hope my story demonstrates that with the right support, determination, and a willingness to carve your own path, anything is possible.”

The University of the Free State is proud to have played a role in Dippenaar’s academic journey, fostering her growth and expertise in business management. Her achievement is a testament to the institution’s commitment to academic excellence and innovation.

News Archive

Nano research at the UFS opens door to smart drugs
2011-06-27

 

Prof. Lodewyk Kock, outstanding professor in our Department of Microbial, Biochemical and Food Biotechnology

Novel antifungal, anticancer and anti-malaria drugs that have been identified in the research of Prof. Lodewyk Kock, outstanding professor in the Department of Microbial, Biochemical and Food Biotechnology at our university, will be disclosed later this year at major international conferences in Asia, Europe and the USA. Prof. Kock will be the keynote speaker at these conferences. 

His presentations will be based on the department’s discovery of yeast assays linked to a new nanotechnology for medicine. The assays were recently discovered by his group and can be applied in the development of novel antifungal, anticancer and anti-malaria drugs.
 
Prof. Kock’s focused research at the university, which now also includes his novel nanotechnology for Biology, began in 1982 in collaboration with Prof. Pieter van Wyk (Centre for Microscopy). He recently collaborated with Prof. Hendrik Swart (Department of Physics).
 
Prof. Kock says the development of novel anti-malaria drugs in particular is getting attention across the world due to the high rates of morbidity and mortality caused by the disease worldwide. Approximately 225 million people are infected annually and about a million (many in Africa) die each year. “Many potential smart drugs have been identified with this research and should now be tested further,” says Kock.
  
These new drugs will be disclosed during Prof. Kock’s keynote addresses at the International Conference and Exhibition on Pharmaceutical Regulatory Affairs in Baltimore, USA, from 6 to 7 September 2011, the Medichem 2011 in Beijing, China from 9 to 11 August 2011 and the XVI Congress of European Mycologists in Greece, from 19 to 23 September 2011.

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept